Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB
Mandate

Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB

November 29, 2021 Employment and Benefits Commercial Agreements Intellectual Property IT, Telecommunications and Outsourcing M&A

Established in 2015, with headquarters in Stockholm, Spendency has grown into a leading spend analytics provider.

Connected directly to the clients’ ERP and/or procurement system, Spendency helps its customers to collect, enrich and normalise supplier data. Spendency serves a vast customer base of more than 100 customers and over 1,500 users. Through the acquisition, Onventis strategically expands its product offering within spend analytics.

Vinge’s team consisted of Filip Öhrner and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (Agreements), Karolina Fuhrman (GDPR/IT), Arvid Axelryd (IP) and Jessica Henning (VDR).

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026